Alltrna
MA - CambridgeBiotechnology
Focus: Alltrna is a Cambridge-based biotechnology company pioneering tRNA therapies as a novel disease-agnostic form of genetic medicine. The company is public-stage and focused on gene therapy applications.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$6B
Open Jobs
3
Should You Work at Alltrna?
AI assessmentAlltrna offers early-stage science appeal in a differentiated modality but presents significant organizational volatility and financial uncertainty for risk-averse candidates.
Why Work Here
- Ground-floor opportunity in a novel therapeutic modality (tRNA therapies) with first clinical trial launching in 2026, per Endpoints News
- Established public biotech with backing to pursue ambitious genetic medicine programs
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alltrna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.